相似文献
1
Editorial: Theranostics as a driving force in nuclear medicine.
Front Oncol. 2024 Sep 6;14:1468357. doi: 10.3389/fonc.2024.1468357. eCollection 2024.
2
Synthesis of DOTA-Based Sc Radiopharmaceuticals Using Cyclotron-Produced Sc as Exemplified by [Sc]Sc-PSMA-617 for PSMA PET Imaging.
Methods Protoc. 2025 Jun 4;8(3):58. doi: 10.3390/mps8030058.
3
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.
J Nucl Med. 2024 Dec 3;65(12):1952-1958. doi: 10.2967/jnumed.124.268037.
4
Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes.
Front Nucl Med. 2024 Nov 27;4:1480471. doi: 10.3389/fnume.2024.1480471. eCollection 2024.
5
Dual Targeting of Prostate-Specific Membrane Antigen and Fibroblast Activation Protein: Bridging Prostate Cancer Theranostics with Precision.
ACS Appl Bio Mater. 2025 Feb 17;8(2):962-979. doi: 10.1021/acsabm.4c01914. Epub 2025 Feb 3.
6
Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors.
Mol Imaging. 2022 Apr 15;2022:5358545. doi: 10.1155/2022/5358545. eCollection 2022.
7
Evaluation of Lu and Sc Picaga-Linked, Prostate-Specific Membrane Antigen-Targeting Constructs for Their Radiotherapeutic Efficacy and Dosimetry.
Mol Pharm. 2021 Dec 6;18(12):4511-4519. doi: 10.1021/acs.molpharmaceut.1c00711. Epub 2021 Oct 29.
8
A Case Report on the Dramatic Response of Lu-PSMA Therapy for Metastatic Prostate Cancer.
Curr Med Imaging. 2025;21:e15734056362468. doi: 10.2174/0115734056362468250709045212.
9
Synthesis of Ac-PSMA-617 for Preclinical Use.
Curr Radiopharm. 2022;15(2):96-103. doi: 10.2174/1874471014666210709094616.
10
Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine.
J Nucl Med. 2020 Mar;61(3):311-318. doi: 10.2967/jnumed.118.220665. Epub 2020 Jan 10.
本文引用的文献
1
Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.
Int J Mol Sci. 2024 Jan 11;25(2):933. doi: 10.3390/ijms25020933.
2
3BP-3940, a highly potent FAP-targeting peptide for theranostics - production, validation and first in human experience with Ga-68 and Lu-177.
iScience. 2023 Nov 23;26(12):108541. doi: 10.1016/j.isci.2023.108541. eCollection 2023 Dec 15.
3
At the right dose: personalised (N-of-1) dosing for precision oncology.
Eur J Cancer. 2023 Nov;194:113359. doi: 10.1016/j.ejca.2023.113359. Epub 2023 Sep 24.
4
Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
Semin Nucl Med. 2023 Sep;53(5):663-686. doi: 10.1053/j.semnuclmed.2023.06.007. Epub 2023 Jul 18.
5
Birth of the Beta-knife Thyroidectomy: The Radiance of Saul Hertz.
Am Surg. 2023 May;89(5):2145-2149. doi: 10.1177/00031348211060463. Epub 2022 Jan 26.
6
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
7
An Improved At-Labeled Agent for PSMA-Targeted α-Therapy.
J Nucl Med. 2022 Feb;63(2):259-267. doi: 10.2967/jnumed.121.262098. Epub 2021 Jun 4.
8
Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine.
J Nucl Med. 2020 Mar;61(3):311-318. doi: 10.2967/jnumed.118.220665. Epub 2020 Jan 10.
9
Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms.
J Nucl Med. 2018 Jun;59(6):871-877. doi: 10.2967/jnumed.117.203570. Epub 2018 Mar 15.
10
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
Zotero 插件